Resource Allocation for Different Types of Vaccines against COVID-19: Tradeoffs and Synergies between Efficacy and Reach

Daniel Kim

H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta,

GA 30332, email: dkim608@gatech.edu

Pelin Pekgün, Ph.D.

Moore School of Business, University of South Carolina, Columbia, SC 29208,

email: pelin.pekgun@moore.sc.edu

İnci Yildirim, M.D., Ph.D.

Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale School of Medicine and

Yale Institute of Global Health, 1 Church Street, New Haven, CT 06510,

email: inci.yildirim@yale.edu

Pınar Keskinocak, Ph.D.

H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta,

GA 30332, email: pinar@isye.gatech.edu

Corresponding Author:

Pınar Keskinocak, Ph.D.

H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta,

GA 30332, email: pinar@isye.gatech.edu

Word Count (Abstract): 256 Word Count (Text): 3640

Figure/Table Count: 5 References Count: 37

Abstract:

Objective: Vaccine shortage and supply-chain challenges have caused limited access by many resource-
limited countries during the COVID-19 pandemic. One of the primary decisions for a vaccine-ordering
decision-maker is how to allocate the limited resources between different types of vaccines effectively.
We studied the tradeoff between efficacy and reach of the two vaccine types that become available at
different times.

Methods: We extended a Susceptible-Infected-Recovered-Deceased (SIR-D) model with vaccination, ran
extensive simulations with different settings, and compared the level of *infection attack rate* (IAR) under
different reach ratios between two vaccine types under different resource allocation decisions.

Results: We found that when there were limited resources, allocating resources to a vaccine with high
efficacy that became available earlier than a vaccine with lower efficacy did not always lead to a lower
IAR, particularly if the former could vaccinate less than 42.5% of the population (with the selected study
parameters) who could have received the latter. Sensitivity analyses showed that this result stayed robust
under different study parameters.

Conclusions: Our results showed that a vaccine with lower resource requirements (wider reach) can
significantly contribute to reducing IAR, even if it becomes available later in the pandemic, compared to a
higher efficacy vaccine that becomes available earlier but requires more resources. Limited resource in
vaccine distribution is significant challenge in many parts of the world that needs to be addressed to
improve the global access to life-saving vaccines. Understanding the tradeoffs between efficacy and reach
is critical for resource allocation decisions between different vaccine types for improving health outcomes.

51
52 **Keywords**: resource allocation; vaccination; disease modeling; COVID-19; vaccine efficacy

54 **Preference for colors** in Tables and Figures: Online Only

INTRODUCTION

In December 2019, the novel coronavirus (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), was first detected in Wuhan, China. As of October 2021, approximately 236 million COVID-19 cases have been reported worldwide [1]. Despite the development of effective vaccines at unprecedented speed and high vaccination rates in some countries, vaccine availability remains scarce and vaccination rates remain low in many countries; for example, only approximately 2.3% of people in low-income countries received at least one dose of vaccine as of October 2021 [2].

The procurement and dissemination of vaccines, especially the mRNA vaccines, which require ultra-cold storage, have been particularly challenging in low-income countries [3, 4]. Even before the vaccines were produced, high-income countries had purchased or reserved large amounts of vaccines [5]. Consequently, low- and middle-income countries had difficulty in procuring vaccines early and faced varying prices and unstable supply chains, similar to what was also experienced during the 2009 H1N1 pandemic [6, 7]. Key ingredients, such as lipid nanoparticles used in the production of high-efficacy mRNA vaccines have been in short supply [8, 9]. The limited availability of cold-chain storage and logistics capacity can impede the distribution of mRNA vaccines in many regions. By contrasts, non-mRNA vaccines, such as adenovirus-vectored vaccines, can be transported and stored at lower temperatures, enabling easier distribution and broader reach with less resources.

In general, the procurement and distribution of mRNA versus non-mRNA vaccines require more "resources" such as financial resources, logistics and storage capacities, or healthcare facilities and personnel. Limited vaccine supply in resource limited settings and estimated vaccine shortage for 2022 are real daily life challenges that we have to resolve to improve the global access to life-saving pandemic vaccine [10, 11]. Hence, there is often a tradeoff between efficacy and reach across different vaccines because the resource requirements impact the speed and reach of vaccine distribution efforts, and, consequently, impact how many people gain timely access to vaccination and the level of protection in the population. A recent modeling study considered various efficacies for a single type of vaccine [12, 13],

and showed that the wider reach (i.e., lower resource requirements) of the vaccine could result in

significant reductions in total infections.

The main goal of this study is to understand this tradeoff between efficacy and reach while

developing and deploying vaccine procurement and distribution plans, i.e., how to allocate limited

resources between two types of vaccines: (i) a high efficacy vaccine that becomes available earlier but

requires more resources, versus (ii) a low-efficacy vaccine that becomes available later but requires less

resources. We developed an extended Susceptible-Infected-Recovered-Deceased (SIR-D) simulation

model to analyze and assess the impact of resource allocation decisions across two types of vaccines on

population health outcomes, such as the proportion of the population infected during the course of the

disease. This study provides insights to decision-makers regarding resource planning and allocation when

multiple types of vaccines are available during a pandemic. The results suggest that prioritizing the high-

efficacy vaccine in resource allocation does not always lead to the best health outcomes; under resource

constraints, utilizing a combination of high- and low- efficacy vaccines might reduce the percentage of

the population infected and reduce the infection peak.

METHODS

Two Types of Vaccines

We considered two types of single-dose vaccines that become available at different times. The

vaccine with high efficacy (vaccine-H) becomes available sooner than the vaccine with lower efficacy

(vaccine-L). A resource of K units is available daily (K=1 million in the simulation), and a fixed

proportion $a_H, a_L \in [0,1]$ of the capacity K is allocated to vaccine-H and vaccine-L, respectively, where

$a_H + a_L = 1$. For a given K, K people can receive vaccine-L (i.e., one unit of resource is needed for one

person to receive vaccine-L), whereas only a λK people ($\lambda < 1$) can receive vaccine-H. We denote λ as

the *reach ratio*, where lower λ values indicate higher resource requirements for vaccine-H relative to

vaccine-L. Hence, given daily capacity K, reach ratio λ, and allocation decisions a_H, a_L ($a_H + a_L = 1$),

the number of people who can receive vaccine-H and vaccine-L daily are $a_H \lambda K$ and $a_L K$, respectively.

In the main scenario, we set the efficacy of vaccine-H at 90% and vaccine-L at 70%, and vaccine-

H becomes available three weeks earlier than vaccine-L. We assumed that during the period when only

one vaccine type is available, any unused daily resources are lost.

Compartmental epidemiological model

In the extended SIRD model, each person is in one of the following compartments at a given

time: *Susceptible* (S), *Susceptible-i* (S_i, $i =$ H or L), *Symptomatic-Infected* (I^S), *Asymptomatic-Infected*

(I^A), *Quarantined* (Q), *Vaccinated-i* (V_i), *Recovered* (R), and *Deceased* (D). *Susceptible* (unvaccinated)

population transitions to one of the *Symptomatic-Infected* (I^S) or *Asymptomatic-Infected* (I^A)

compartments after *infectious contact* with either infected population. Depending on the resource

allocation decisions and vaccine efficacy, a proportion of Susceptible population who receives vaccine-i

($i =$ H or L) transitions to *Vaccinated-i* (V_i), whereas the others transition to *Susceptible-i* (S_i; those who

received vaccine-i but did not develop immunity). Symptomatic-Infected population transitions to one of

the *Quarantined* (Q), *Recovered* (R) or the *Deceased* (D) compartments. Asymptomatic-Infected

population transitions to *Recovered* (R) compartment. The transition diagram of the extended SIRD

model is depicted in Figure 1.

Figure 1: Transmission diagram of the extended SIR-D model, in which the population is stratified based upon the epidemiological status; : Transmission rate due to infectious contacts between a susceptible individual and either a symptomatic or asymptomatic patient; : Efficacy of vaccine-H and vaccine-L; : ratio of the daily vaccine capacity to the size of the susceptible population (i.e., and); : Self-isolation rate; : Recovery rate of a symptomatic or asymptomatic patient; : Death rate of a symptomatic patient.

The parameter values in the SIR-D model were chosen based on the SARS-CoV-2 characteristics.

The Centers for Disease and Prevention (CDC) in the United States estimated that 70% of COVID-19

infections are symptomatic ([14]. The durations of the mean presymptomatic infectious period,

the median asymptomatic infectious period, and the mean time from symptom onset to two negative RT-

PCR tests are estimated as 6 days [15], 6.5–9.5 days, and 13.4 days [16], respectively. Hence, we set the

recovery rates of asymptomatic patients ( ) and symptomatic patients ( ) at 1/8 and 1/16, respectively.

The CDC reported that the number of days from symptom onset to SARS-CoV-2 test ranges between 0

and 4 days [14]. Considering the time until the test result becomes available and the number of people

getting tested, we set the quarantine rate ($\phi = 1/12$), by which the symptomatic infectious population

(I^S) move to the Quarantined compartment (Q). Infection fatality rate (IFR-S) for symptomatic infectious

population is estimated as 1.3% in the United States [13] and lower in a typical low-income country with

younger population [17, 18]. Hence, we set the death rate (μ) to be 0.0015, at which IFR-S is

approximately 1.07% in the simulations without the vaccines. The infectivity of a disease, represented by

reproduction number (R_0), is estimated as 2.5 by [14]; the symptomatic-transmission rate (β^S) is set at

0.21 in the main scenario of the simulation, and the asymptomatic-transmission rate (β^A) is set at 75% of

the symptomatic-transmission rate [19].

We ran the simulation using R-software with a population size of 330 million. Since our main goal is

to analyze the impact of resource allocation of multiple types of vaccines, we started the simulation only

after vaccine-H became available (Day 1). For the initial population size (immediately before vaccine-H

becomes available) in each compartment, we set $S = 94.86\%, I^S = 1.02\%, I^A = 0.58\%, Q =$

$0.34\%, R = 3.10\%,$ and $D = 0.01\%$, motivated by the COVID-19 statistics recorded on December 14,

2020, the first day of the vaccine distribution in the United States [20, 21]. The simulation was run over a

one-year planning horizon with $a_H = 0$ to 1 ($a_H + a_L = 1$; increments of 0.1), and $\lambda = 0.005$ to 0.995

(increments of 0.005).

We compared *infection attack rate* (IAR) as the main health outcome, peak day (the day when the

peak infections occur), and peak percentage (percentage of the population that is newly infected on the

peak day) under different scenarios to evaluate the impact of the resource allocation decisions.

In addition to the main scenario, we performed extensive sensitivity analyses. We simulated 21

additional scenarios with different 1) infectivity of the disease with reproduction numbers ($R_0 =$

$2, 2.25, 2.75$ and 3) and corresponding transmission rates, 2) timing when vaccine-L becomes available

within the range of 0 to 8 weeks after vaccine-H becomes available (increments of 1 week), and 3)

efficacy levels of vaccine-H within the range of 85% to 95% (increments of 1%). We also assessed six

alternative scenarios, in which 1) vaccine-H becomes available within the range of 1 to 4 weeks after

vaccine-L becomes available (increments of 1 week; four scenarios), and 2) the initial population size of

each compartment is different from the main scenario (two scenarios).

RESULTS

In the main scenario, in the absence of vaccines, approximately 50.18% of the population is infected,

the peak day is 39 (from the start of the vaccination), and the peak percentage is 0.65%.

Infection Attack Rate

Table 1 and Figure 2 show the IAR under different reach ratios and resource allocation decisions.

When the reach ratio is low, i.e., $\lambda \leq 0.425$: (i) Allocating all resources to vaccine-L (i.e., $a_H = 0, a_L =$

1) minimizes the IAR. (ii) Comparing the optimal allocation $a_L = 1$ to allocating all resources to vaccine-

H ($a_H = 1$), the difference between the IARs under $a_L = 1$ and $a_H = 1$ increases as λ decreases. For

example, when $\lambda = 0.2$ and $\lambda = 0.425$, the differences in IAR are 4.83% and 0.293%, respectively,

corresponding to approximately 16 million infections (Figure S1) and 0.97 million infections that could

have been averted by allocating all the resources to vaccine-L versus vaccine-H.

When $\lambda \geq 0.455$, allocating the resources entirely to vaccine-H (i.e., $a_H = 1, a_L = 0$) minimizes

the IAR. When the reach ratio falls within $0.425 \leq \lambda \leq 0.455$, the resources are allocated between

vaccine-L and vaccine-H, with the allocation to vaccine-H increasing in λ. Figure 3 presents contour plots

of IAR under various λ and a_H values.

Peak Percentage

Table 12 shows the peak percentage under different reach ratios and resource allocation decisions.

The peak percentage is minimized by allocating all resources to vaccine-L and vaccine-H when $\lambda \leq$

0.165 and $\lambda \geq 0.21$, respectively; when $0.165 \leq \lambda \leq 0.21$, peak percentage is minimized by splitting the

resources between the two types of vaccines.

Table 1: Infection attack rate (IAR) in percentage under different resource allocation decisions and reach
ratios

(a_H, a_L)	Reach ratio (λ)						
	0.425	0.43	0.435	0.44	0.445	0.45	0.455
(1, 0)	41.009	40.916	40.823	40.730	40.638	40.546	40.454
(0.9, 0.1)	40.951	40.868	40.786	40.704	40.622	40.539	40.458
(0.8, 0.2)	40.901	40.828	40.756	40.684	40.612	40.540	40.468
(0.7, 0.3)	40.887	40.795	40.732	40.670	40.608	40.546	40.484
(0.6, 0.4)	40.820	40.767	40.714	40.662	40.609	40.556	40.504
(0.5, 0.5)	40.789	40.746	40.702	40.659	40.615	40.572	40.529
(0.4, 0.6)	40.764	40.730	40.795	40.661	40.626	40.592	40.558
(0.3, 0.7)	40.745	40.719	40.693	40.668	40.642	40.617	40.591
(0.2, 0.8)	40.730	40.713	40.796	40.679	40.663	40.646	40.629
(0.1, 0.9)	40.720	40.712	40.704	40.795	40.687	40.679	40.670
(0, 1)	40.716	40.716	40.716	40.716	40.716	40.716	40.716

191   *Table 2: Peak percentage under different resource allocation decisions and reach ratios*

(a_H, a_L)	Reach ratio (λ)									
	0.165	0.17	0.175	0.18	0.185	0.19	0.195	0.2	0.205	0.21
(1, 0)	0.60628	0.60517	0.60409	0.60301	0.60193	0.60085	0.59978	0.59871	0.59764	0.59657
(0.9, 0.1)	0.60533	0.60436	0.60339	0.60242	0.60145	0.60048	0.59951	0.59855	0.59758	0.59662
(0.8, 0.2)	0.60441	0.60355	0.60268	0.60182	0.60096	0.60010	0.59925	0.59843	0.59761	0.59679
(0.7, 0.3)	0.60359	0.60287	0.60215	0.60142	0.60070	0.59998	0.59926	0.59854	0.59782	0.59710
(0.6, 0.4)	0.60298	0.60236	0.60174	0.60112	0.60050	0.59988	0.59927	0.59865	0.59803	0.59742
(0.5, 0.5)	0.60236	0.60185	0.60133	0.60081	0.60030	0.59978	0.59927	0.59876	0.59826	0.59776
(0.4, 0.6)	0.60187	0.60148	0.60108	0.60069	0.60029	0.59990	0.59951	0.59911	0.59872	0.59833

(0.3, 0.7)	0.60155	0.60125	0.60095	0.60066	0.60036	0.60007	0.59977	0.59948	0.59918	0.59889
(0.2, 0.8)	0.60122	0.60102	0.60082	0.60063	0.60043	0.60023	0.60003	0.59984	0.59964	0.59944
(0.1, 0.9)	0.60092	0.60083	0.60073	0.60064	0.60054	0.60045	0.60035	0.60026	0.60017	0.60007
(0, 1)	0.60086	0.60086	0.60086	0.60086	0.60086	0.60086	0.60086	0.60086	0.60086	0.60086

193   .

195   *Figure 2: Infection attack rate (IAR) under different resource allocation decisions (with different reach*
196   *ratios   and   from top to bottom).*

Figure 3: Contour plot of infection attack rate under different reach ratios ( ) and resource allocation
decisions ( ).

Alternative Scenarios

The simulation results of the alternative scenarios with different vaccine efficacies, timings and

infectivity of the disease are reported in Supplementary Materials. We observed a similar pattern as in the

main scenario in all alternative scenarios. In addition, compared to the main scenario, the maximum

below which allocating all resources to vaccine-L minimizes the IAR is lower when the efficacy of

vaccine-H is higher, the timing of vaccine-L's availability is delayed, or the infectivity of the disease is

higher. In contrast to the main scenario, if vaccine-H becomes available *later* than vaccine-L, specifically

by more than a week, allocating all resources to vaccine-L minimizes the IAR for all   .

DISCUSSION

In this study, we developed an extended SIR-D simulation model and examined the impact of resource allocation decisions across two types of vaccines, namely, a high efficacy vaccine (vaccine-H) that becomes available earlier during the pandemic but requires more resources, and a lower efficacy vaccine (vaccine-L) that becomes available later and requires less resources (i.e., has wider *reach*). For each unit of resource, one person can be vaccinated with vaccine-L whereas $\lambda \leq 1$ person can be vaccinated with vaccine-H, where λ is defined as the reach ratio. The higher the reach ratio, the wider the distribution of vaccine-H relative to vaccine-L given limited available resources. Our results show that the allocation of limited resources across two vaccine types depends heavily on both the vaccine efficacies and the reach ratio; in particular, there are many scenarios where allocating part or all of the resources to the low efficacy vaccine might lead to better outcomes as measured by the infection attack rate or the peak percentage.

The resource allocation decision is complex due to the tradeoff between efficacy and reach. The more the resources allocated to vaccine-H, the lower the resources remaining for vaccine-L and the lower the total number of people vaccinated (since vaccine-L requires less resources to vaccinate each person). Thus, the reach of vaccine-H needs to be above a certain threshold for it to receive some of the resources.

Our results identified a clear threshold of the reach ratio below which allocating resources entirely to vaccine-L (i.e., $a_L = 1$) minimizes the IAR. With the selected parameters in the main scenario, the threshold was $\lambda = 0.425$, indicating that if vaccine-H reaches 42.5% or less of the population who could have received vaccine-L, then vaccine-H is *highly* resource-intensive (Table 1 and Figure 2). When vaccine-H receives some resource allocation, due to its earlier availability and higher efficacy, more people can get vaccinated and build full immunity in the earlier stages of the disease transmission. However, due to its lower reach level, the rate of decrease in the number of daily infections over time is lower than the rate when the resources are allocated entirely to vaccine-L, which leads to an overall higher IAR in the long term.

While vaccine-L is preferred over a highly resource-intensive vaccine-H, allocating the resources to

vaccine-H may achieve a lower IAR when the infectivity of the disease is more severe. Non-

pharmaceutical interventions, such as social distancing, mask usage, and school closure, have been

deployed during a pandemic and found to be effective in reducing the reproduction number [22-27].

Depending on the various interventions and the disease's unique infectivity level, different resource

allocation decisions need to be made. Our results showed that when the infectivity was high, the

implementation of a prompt intervention with vaccine-H was required to prevent a large-scale infection,

and, therefore, the threshold of the reach ratio was lower than that in the main scenario (Table S2). This

result is consistent with the findings of [24], where the authors studied the impact of the implementation

of both non-pharmaceutical interventions and a *single* vaccine type with varying efficacy and coverage.

The timing of vaccine availabilities also influences the threshold of the reach ratio and subsequently

the resource allocation decisions. When the timing of vaccine-L's availability got delayed, we observed

that even when it became available after the peak day, the threshold of the reach ratio was lower than that

in the main scenario (Table S3 and Figure S2). This indicates that vaccine-H should receive the entire

resources since wider infection control with vaccine-L becomes difficult as many get infected until it

becomes available. In contrast, when vaccine-H became available *later* than vaccine-L, by more than a

week, vaccine-H should receive some resource allocation only when the reach ratio is $\lambda \geq 1$, requiring

the reach of vaccine-H at least as wide as that of vaccine-L (Table S5). Duijzer et al. (2018) performed an

analytical analysis of the resource allocation to two types of vaccines with different efficacies and time of

availabilities using a simple SIR model [28]. Under the setting in which vaccine-H became available later

than vaccine-L and both vaccines had the same *reach* levels, they showed that allocating the resources

entirely to the vaccine with the earlier availability was favored if the later vaccine became available too

late, which is consistent with the results of our alternative scenarios.

In addition, we observed a lower threshold for the reach ratio when the availabilities of both vaccines

got delayed. Many low- and middle-income countries receive their first batches of vaccines much later –

after the disease has already spread widely. During this delay-period, the active and cumulative numbers

of infection increase, putting the more susceptible population at risk of infection. Consequently, allocating

more resources to the resource-intensive vaccine-H, which becomes available early, may bring larger

health benefits than vaccine-L (Table S6 and S7). Thus, despite the difference in the efficacy levels of

each vaccine type, depending on the timing of availability and the reach ratio, the decision of which

vaccine type should be allocated more resources to minimize the IAR changes significantly. Policymakers

must consider the timing of availability for each vaccine type and see if the reach of the later vaccine is

wide enough to slow down the infections that are expected to occur during the delay-period.

While the effort of developing a higher efficacy vaccine is significant, our study showed that the

impact of increasing efficacy level for vaccine-H gradually diminishes, and a greater health benefit can be

achieved if more effort is exerted on achieving a wider reach. As the efficacy of vaccine-H increases, a

lower level of IAR is achieved as more people are likely to become fully protected against the disease

upon the vaccination (Figure S3). However, the rate of the reduction in IAR decreases in the efficacy for

vaccine-H, and a relatively large reduction in IAR rather be achieved via increasing the reach ratio

(Figure S4). If a decision-maker has the means of increasing the reach ratio by either reducing the

resource requirements of vaccine-H relative to vaccine-L or increasing its capabilities to cover more

individuals with vaccine-H given the resource requirements, this is always beneficial as it increases the

number of vaccinated people with a limited amount of resources.

Increasing the reach ratio, however, may imply different levels of complexity depending on how it is

defined in a given context. For example, low-income countries generally suffer from supply chain

challenges (manufacturing, distribution, and storage) of vaccines against various diseases [29-32]. Many

low- and, even, middle-income countries have faced supply chain challenges even more during the

COVID-19 pandemic since mRNA vaccines, which are more effective and became available sooner than

the other vaccine types, similar to the vaccine-H in our model, are produced based on a new vaccine

technology and require colder temperatures than influenza vaccines [33, 34]. On the other hand, the

potential solutions to these challenges, such as sharing vaccine technology with low- and middle-income

countries and establishing an advanced cold-chain infrastructure, and, therefore, increasing the reach ratio,

could be costly and time-consuming [35]. Such scenarios would correspond to the low values of the reach

ratios in our models, where a decision-maker may not have much capability to change those ratios but

treat as given. In such a case, the decision-maker can still minimize IAR by allocating more of its

available resources to the lower efficacy vaccine given its potential wider reach, rather than putting a

significant effort into trying to incrementally increase the reach ratio and allocate resources to vaccine-H

(Figure 3). This also implies that if some individuals must be vaccinated early (e.g., frontline workers) but

vaccine-H is too resource-intensive, the decision-maker should procure the smallest amount of vaccine-H

that is enough to cover those individuals, which still results in a smaller IAR than investing the entire

resources into vaccine-H and/or putting effort into increasing the reach ratio slightly.

Similar to the case of minimizing the IAR, our results identified the thresholds of the reach ratio,

below which allocating the resources entirely to vaccine-L minimizes the peak percentage. However, this

threshold is a lot smaller than the threshold that minimizes IAR (Table 2 and Figure S1). The

implementation of effective vaccines as early as possible reduces the number of susceptible populations

who could have had infectious contacts if the vaccines were not available. This leads to a slower rate of

infections and a "flattened" curve of the pandemic [36]. When minimizing the peak percentage,

policymakers often focus on the health benefits in the short-term, hoping the intervention prevents a

large-scale infection within a small time of period rather than the overall infection levels throughout the

course of the disease. If vaccine-H is moderately resource intensive so that allocating resources to

vaccine-H minimizes the peak percentage but not the IAR, policymakers must make the resource

allocation decision carefully according to the goal of the vaccination program. If the goal is to lower the

peak percentage such that it would not exceed the local healthcare capacity but at the same time to reduce

the infection levels over the long term, they may choose to allocate some resources to both vaccine types .

We acknowledge some limitations of this study. In our model, we used a simple compartment

model to evaluate different strategies of resource allocation between different vaccine types without

confounding the model with the effects of other interventions. However, the model can be extended to

reflect disease transmission under such settings. In addition, our extended SIR-D model does not fully

capture the potential trajectory of an infectious disease over its lifetime. There could be additional stages

(compartments), such as *presymptomatic infected* individuals who are exposed to the virus but do not

develop symptoms yet or *diagnosed/undiagnosed* individuals who are infected, get tested, and isolate

themselves upon their decisions. Another model extension could be temporarily separating individuals

who strictly follow non-pharmaceutical interventions from the susceptible population. Individuals who

decide to stop conforming to the interventions may re-enter the susceptible populations during a pandemic,

as considered in [37]. Some other extensions include a phased rollout of vaccines, instead of an

immediate deployment as in our model, and different number of doses each vaccine type requires, etc.

Overall, our results suggest that allocating limited resources towards a vaccine with high efficacy

that becomes available earlier than a vaccine with lower efficacy may not always result in increased

benefits of a vaccine upon its implementation, especially if the latter can be distributed more widely. In

fact, this may result in a significant deterioration in the infection attack rates if the high-efficacy vaccine

is highly resource intensive, relative to the low-efficacy one, such that only a few people can be

vaccinated each day. Therefore, identifying the resource intensity for each vaccine type as a function of

their efficacy levels, timelines, and disease characteristics, is critical for resource allocation decisions, as

there is a clear threshold for which vaccine type should be favored, and a significant improvement in

health outcomes can be achieved. Manufacturing an mRNA-based vaccine is based on a new vaccine

development technology and disseminating the vaccine have been challenging due to its stringent supply-

chain requirements, especially in resource-limited countries. Improving the global access to life-saving

vaccines by not only building a suitable infrastructure for effective distribution and storage of mRNA-

based vaccines but also considering the tradeoffs and synergies between efficacy and reach is critical. We

335 hope that this study can provide guidance to decision-makers in their resource planning for different

336 vaccine types to better prepare for future pandemics.

337 1. World Health Organization. *WHO Coronavirus Disease (COVID-19) Dashboard.* 2020 [cited 2021
338  Oct. 6]; Available from: https://covid19.who.int.
339 2. Ritchie, H., et al. *Coronavirus pandemic (COVID-19).* Our World In Data 2020 Oct. 6, 2021 [cited
340  2021 Oct. 6]; Available from: https://ourworldindata.org/coronavirus.
341 3. Acharya, K.P., T.R. Ghimire, and S.H. Subramanya, *Access to and equitable distribution of COVID-*
342  *19 vaccine in low-income countries.* npj Vaccines, 2021. **6**(1): p. 54.
343 4. Tregoning, J.S., et al., *Progress of the COVID-19 vaccine effort: viruses, vaccines and variants*
344  *versus efficacy, effectiveness and escape.* Nature Reviews Immunology, 2021: p. 1-11.
345 5. Choi, E.M., *COVID-19 vaccines for low- and middle-income countries.* Transactions of the Royal
346  Society of Tropical Medicine and Hygiene, 2021. **115**(5): p. 447-456.
347 6. Fidler, D.P., *Negotiating equitable access to influenza vaccines: global health diplomacy and the*
348  *controversies surrounding avian influenza H5N1 and pandemic influenza H1N1,* in *Negotiating*
349  *and navigating global health: case studies in global health diplomacy.* 2012, World Scientific. p.
350  161-172.
351 7. Fischer, W.A., et al., *Global burden of influenza: contributions from resource limited and low-*
352  *income settings.* Global heart, 2014. **9**(3): p. 325.
353 8. Rodgers, L. *Covid vaccines: Why a giant plastic bag shortage is slowing the rollout.* 2021 [cited
354  2021 August 1]; Available from: https://www.bbc.com/news/health-57024322.
355 9. Rudnitsky, J. *Russia's Global Vaccine Ambitions Stumble During Supply Shortage.* 2021 [cited
356  2021 August 1]; Available from: https://www.bloomberg.com/news/articles/2021-07-30/russia-
357  s-global-vaccine-ambitions-stumble-amid-supply-shortage.
358 10. Paton, J. and C. Gretler. *Vaccine Shortages Hit Global Supply Program, Halting Rollouts.* 2021
359  [cited 2021 Sep 24]; Available from: https://www.bloomberg.com/news/articles/2021-06-
360  22/will-there-be-enough-vaccines-covax-is-running-out.
361 11. World Health Organization. *Joint COVAX Statement on Supply Forecast for 2021 and early 2022.*
362  2021 [cited 2021 Sep 24]; Available from: https://www.who.int/news/item/08-09-2021-joint-
363  covax-statement-on-supply-forecast-for-2021-and-early-
364  2022#:~:text=According%20to%20its%20latest%20Supply,coverage%20countries%20to%20prior
365  itize%20COVAX.
366 12. Paltiel, A.D., et al., *Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy:*
367  *Study examines how definitions and thresholds of vaccine efficacy, coupled with different levels*
368  *of implementation effectiveness and background epidemic severity, translate into outcomes.*
369  Health Affairs, 2021: p. 10.1377/hlthaff. 2020.02054.
370 13. MacIntyre, C.R., V. Costantino, and M. Trent, *Modelling of COVID-19 vaccination strategies and*
371  *herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia.* Vaccine, 2021.
372 14. Centers for Disease Control and Prevention. *COVID-19 Pandemic Planning Scenarios.* 2020
373  [cited 2021 Aug. 20]; Available from: https://www.cdc.gov/coronavirus/2019-
374  ncov/hcp/planning-scenarios.html.
375 15. McAloon, C., et al., *Incubation period of COVID-19: a rapid systematic review and meta-analysis*
376  *of observational research.* BMJ Open, 2020. **10**(8): p. e039652.
377 16. Byrne, A.W., et al., *Inferred duration of infectious period of SARS-CoV-2: rapid scoping review*
378  *and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases.* BMJ
379  open, 2020. **10**(8): p. e039856.

17. Basu, A., *Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases In The*
United States: Study estimates the COVID-19 infection fatality rate at the US county level. Health
Affairs, 2020. **39**(7): p. 1229-1236.
18. Brazeau, N., et al., *Report 34: COVID-19 infection fatality ratio: estimates from seroprevalence.*
2020.
19. Oran, D.P. and E.J. Topol, *Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review.*
Annals of internal medicine, 2020. **173**(5): p. 362-367.
20. Worldometer. *COVID-19 Projections.* 2020 [cited 2021 August 1]; Available from:
https://www.worldometers.info/coronavirus/.
21. Centers for Disease Control and Prevention, *COVID Data Tracker.* 2021.
22. Shen, M., et al., *Projected COVID-19 epidemic in the United States in the context of the*
effectiveness of a potential vaccine and implications for social distancing and face mask use.
Vaccine, 2021. **39**(16): p. 2295-2302.
23. Li, Y., et al., *The temporal association of introducing and lifting non-pharmaceutical interventions*
with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131
countries. The Lancet Infectious Diseases, 2021. **21**(2): p. 193-202.
24. Patel, M.D., et al., *Association of Simulated COVID-19 Vaccination and Nonpharmaceutical*
Interventions With Infections, Hospitalizations, and Mortality. JAMA network open, 2021. **4**(6): p.
e2110782-e2110782.
25. Suryanarayanan, P., et al., *AI-assisted tracking of worldwide non-pharmaceutical interventions*
for COVID-19. Scientific data, 2021. **8**(1): p. 1-14.
26. Spouge, J.L., *A comprehensive estimation of country-level basic reproduction numbers R 0 for*
COVID-19: Regime regression can automatically estimate the end of the exponential phase in
epidemic data. PloS one, 2021. **16**(7): p. e0254145.
27. Linka, K., M. Peirlinck, and E. Kuhl, *The reproduction number of COVID-19 and its correlation with*
public health interventions. Computational Mechanics, 2020. **66**(4): p. 1035-1050.
28. Duijzer, L.E., W. van Jaarsveld, and R. Dekker, *The benefits of combining early aspecific*
vaccination with later specific vaccination. European Journal of Operational Research, 2018.
271(2): p. 606-619.
29. Zipursky, S., et al., *Assessing the potency of oral polio vaccine kept outside of the cold chain*
during a national immunization campaign in Chad. Vaccine, 2011. **29**(34): p. 5652-5656.
30. Guignard, A., et al., *Introducing new vaccines in low-and middle-income countries: challenges*
and approaches. Expert review of vaccines, 2019. **18**(2): p. 119-131.
31. Matthias, D.M., et al., *Freezing temperatures in the vaccine cold chain: a systematic literature*
review. Vaccine, 2007. **25**(20): p. 3980-3986.
32. Haidari, L.A., et al., *Augmenting transport versus increasing cold storage to improve vaccine*
supply chains. PloS one, 2013. **8**(5): p. e64303.
33. Nachega, J.B., et al., *Addressing challenges to rolling out COVID-19 vaccines in African countries.*
The Lancet Global Health, 2021. **9**(6): p. e746-e748.
34. United Nations. *COVID-19: First mRNA vaccine tech transfer hub a 'great step forward'.* 2021
[cited 2021 Aug 26]; Available from: https://news.un.org/en/story/2021/06/1094402.
35. Lydon, P., et al., *Health system cost of delivering routine vaccination in low-and lower-middle*
income countries: what is needed over the next decade? Bulletin of the World Health
Organization, 2014. **92**: p. 382-384.
36. Matrajt, L. and T. Leung, *Evaluating the effectiveness of social distancing interventions to delay*
or flatten the epidemic curve of coronavirus disease. Emerging infectious diseases, 2020. **26**(8): p.
1740.

37. Cooper, I., A. Mondal, and C.G. Antonopoulos, *A SIR model assumption for the spread of COVID-*
19 in different communities. Chaos, Solitons & Fractals, 2020. **139**: p. 110057.
429

ACKNOWLEDGEMENT

This research has been supported in part by the following Georgia Tech benefactors: William W. George, Andrea Laliberte, Claudia L. and J. Paul Raines, and Richard E. "Rick" and Charlene Zalesky. This research has also been supported in part by Cooperative Agreement number NU38OT000297 from The Centers for Disease Control and Prevention (CDC) and CSTE and does not necessarily represent the views of CDC and CSTE.

ADDITIONAL INFORMATION

Dr. İnci Yildirim reported being a member of the mRNA-1273 Study Group. Dr. Yildirim has received funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, and Micron. Dr. Pinar Keskinocak received funding to her institution from Merck to conduct non-clinical research. The funders played no role in the study design, data collection, analysis, interpretation, or in writing the manuscript.

AUTHOR CONTRIBUTIONS

D.K., P.K., P.P., and I.Y. conceived the model and contributed to the writing of the manuscript. D.K. contributed to the production of the figures and the tables.

SUPPLEMENTARY MATERIALS

A. Compartmental Model

We extended the susceptible-infected-recovered-deceased (SIR-D) compartmental model to capture the dynamics of COVID-19 transmission, isolation of symptomatic infected individuals, and implementation of two types of vaccines. The list below summarizes the compartments we included in the model:

1. Susceptible

   a. S: Susceptible

   b. S_H: Population who has received vaccine-H but remains susceptible

   c. S_L: Population who has received vaccine-L but remains susceptible

2. Infected

   a. I^S: Symptomatic Infected

   b. I^A: Asymptomatic Infected

   c. Q: Quarantined – infected individuals that do not transmit disease to susceptible populations

3. Vaccinated (Immunized)

   a. V_H: Vaccinated with vaccine-H

   b. V_L: Vaccinated with vaccine-L

4. Recovered

   a. R: Recovered

5. Deceased

   a. D: Deceased

Table S1 below summarizes the epidemiological and vaccine parameters, used in the extended SIR-D

model:

Table S1: Epidemiological and vaccine parameters

Epidemiological Parameters	Value (main scenario)	Description
β^S	0.21	Rate of disease transmission from symptomatic-infected individuals
β^A	0.1575	Rate of disease transmission from asymptomatic-infected individuals
γ^S	1/16	Rate of recovery for symptomatic-infected individuals
γ^A	1/8	Rate of recovery for asymptomatic-infected individuals
γ^Q	1/4	Rate of recovery for quarantined individuals
ϕ	1/12	Rate of isolation by symptomatic-infected individuals
μ	0.0015	Rate of death among symptomatic-infected individuals
p^S	70%	Percentage of symptomatic infection
Vaccine Parameters	**Value (main scenario)**	**Description**
e_H	90%	Efficacy for vaccine-H
e_L	70%	Efficacy for vaccine-L
t_H	Day 1	Time that vaccine-H becomes available
t_L	Day 22	Time that vaccine-L becomes available
K	1,000,000	Daily resource capacity
λ	[.005, .995; .005]	Reach ratio
a_H	[0, 1; 0.1]	Decision of resource allocation to vaccine-H
a_L	[0, 1; 0.1]	Decision of resource allocation to vaccine-L
v_H	$a_H \lambda K / S$	Percentage of susceptible individuals who receive vaccine-H
v_L	$a_L K / S$	Percentage of susceptible individuals who receive vaccine-L

We used the R package *deSolve* to construct the simulation that utilizes the Euler method to solve the

ordinary differential equations below with a step size of 1 day.

$$\frac{dS}{dt} = -v_H S - v_L S - \beta^S (1 - v_H - v_L) S I^S - \beta^A (1 - v_H - v_L) S I^A$$

$$\frac{dS_H}{dt} = (1 - e_H) v_H S - \beta^S S_H I^S - \beta^A S_H I^A$$

$$\frac{dS_L}{dt} = (1 - e_L) v_L S - \beta^S S_L I^S - \beta^A S_L I^A$$

$$\frac{dI^S}{dt} = p^S [\beta^S (1 - v_H - v_L) S I^S + \beta^A (1 - v_H - v_L) S I^A + \beta^S (S_H + S_L) I^S + \beta^A (S_H + S_L) I^A] - \gamma^S I^S - \mu I^S - \phi I^S$$

$$\frac{dI^A}{dt} = (1 - p^S)[\beta^S (1 - v_H - v_L) S I^S + \beta^A (1 - v_H - v_L) S I^A + \beta^S (S_H + S_L) I^S + \beta^A (S_H + S_L) I^A] - \gamma^A I^A$$

$$\frac{dQ}{dt} = \phi I^S - \gamma^Q Q - \mu Q$$

$$\frac{dV_H}{dt} = e_H v_H S$$

$$\frac{dV_L}{dt} = e_L v_L S$$

$$\frac{dR}{dt} = \gamma^S I^S + \gamma^A I^A + \gamma^Q Q$$

$$\frac{dD}{dt} = \mu(I^S + Q)$$

B. Main Scenario – Full Results of the Simulation

Figure S1 shows the full results of the simulation under different reach ratios ( ) and resource allocation decisions (when the main outcome of interest is either the infection attack rate (IAR) or the peak percentage.

(a)   (b)

Figure S1: Main scenario simulation results when the objective is to minimize (a) infection attack rate (%) and (b) peak percentage (%)

C. Sensitivity Analyses

We conducted extensive sensitivity analyses. A total of 21 additional scenarios were tested.

a. The impact of the infectivity of a disease (R_0)

Table S2 shows the IAR under different reach ratios and resource allocation decisions with a specified reproduction number (R_0). It also reports the thresholds of the reach ratio, at or below which vaccine-L is favored entirely ($a_L = 1$) when minimizing IAR ($\hat{\lambda}_{IAR}$) or peak percentage ($\hat{\lambda}_{PP}$), and the thresholds of the reach ratio, at or above which vaccine-H is favored entirely ($a_H = 1$) when minimizing IAR ($\tilde{\lambda}_{IAR}$) or peak percentage ($\tilde{\lambda}_{PP}$), under different efficacies for vaccine-H. Similar to the main scenario, we observe that $\hat{\lambda}_{IAR}$ generally decreases as R_0 increases. However, if vaccine-L becomes available after the peak day, we observe a lower $\hat{\lambda}_{IAR}$. For example, under the scenario where vaccine-L becomes available on day 22, when $R_0 = 2.0$, the peak day ranges between day $10 - 16$, depending on the reach ratio and the resource allocation decision, and $\hat{\lambda}_{IAR} = 0.405$. When $R_0 = 2.75$, the peak day ranges between day $31 - 36$ and $\hat{\lambda}_{IAR} = 0.415$.

Table S2: Infection Attack Rate (%) under different infectivity of a disease

$R_0 = 2.0\ (\beta^S = 0.169118, \beta^A = 0.1268385)$

(a_H, a_L)	Reach ratio (λ)							
	0.405	0.41	0.415	0.42	0.425	0.43	0.435	0.44
$(1, 0)$	20.635	20.587	20.539	20.492	20.445	20.399	20.353	20.307
$(0.9, 0.1)$	20.600	20.558	20.516	20.475	20.434	20.393	20.352	20.311
$(0.8, 0.2)$	20.571	20.534	20.498	20.461	20.426	20.390	20.354	20.319
$(0.7, 0.3)$	20.545	20.514	20.483	20.452	20.421	20.390	20.360	20.329
$(0.6, 0.4)$	20.524	20.498	20.472	20.446	20.419	20.394	20.368	20.342
$(0.5, 0.5)$	20.507	20.485	20.464	20.442	20.421	20.400	20.379	20.357
$(0.4, 0.6)$	20.493	20.476	20.459	20.442	20.425	20.408	20.392	20.375
$(0.3, 0.7)$	20.482	20.469	20.457	20.444	20.432	20.420	20.407	20.395

(0.2, 0.8)	20.474	20.466	20.458	20.449	20.441	20.433	20.425	20.417
(0.1, 0.9)	20.469	20.465	20.461	20.457	20.453	20.449	20.445	20.441
(0, 1)	20.466	20.466	20.466	20.466	20.466	20.466	20.466	20.466

The peak day is day $10 - 16$, depending on the reach ratio (λ) and the resource allocation decision (a_H and a_L). The peak day occurs before vaccine-L becomes available ($t_L = 22$).

$R_0 = 2.25$ ($\beta^S = 0.190258, \beta^A = 0.1426935$)

(a_H, a_L)	Reach ratio (λ)						
	0.425	0.43	0.435	0.44	0.445	0.45	0.455
$(1, 0)$	30.675	30.596	30.517	30.439	30.361	30.283	30.206
$(0.9, 0.1)$	30.622	30.552	30.482	30.413	30.344	30.276	30.207
$(0.8, 0.2)$	30.576	30.515	30.454	30.394	30.333	30.273	30.213
$(0.7, 0.3)$	30.537	30.484	30.432	30.380	30.328	30.276	30.224
$(0.6, 0.4)$	30.503	30.459	30.415	30.371	30.327	30.283	30.239
$(0.5, 0.5)$	30.476	30.439	30.403	30.367	30.331	30.295	30.259
$(0.4, 0.6)$	30.453	30.424	30.396	30.367	30.339	30.310	30.282
$(0.3, 0.7)$	30.436	30.414	30.393	30.372	30.351	30.330	30.309
$(0.2, 0.8)$	30.423	30.409	30.395	30.381	30.367	30.353	30.339
$(0.1, 0.9)$	30.414	30.408	30.401	30.394	30.387	30.380	30.373
$(0, 1)$	30.410	30.410	30.410	30.410	30.410	30.410	30.410

The peak day is day $21 - 38$, depending on the reach ratio (λ) and the resource allocation decision (a_H and a_L). When $a_L = 1$, the peak day is day 30.

$R_0 = 2.75$ ($\beta^S = 0.232538, \beta^A = 0.1744035$)

(a_H, a_L)	Reach ratio (λ)					
	0.415	0.42	0.425	0.43	0.435	0.44
$(1, 0)$	51.735	51.641	51.548	51.455	51.361	51.268
$(0.9, 0.1)$	51.687	51.603	51.520	51.437	51.354	51.271
$(0.8, 0.2)$	51.644	51.571	51.498	51.424	51.351	51.278
$(0.7, 0.3)$	51.608	51.545	51.481	51.418	51.354	51.291
$(0.6, 0.4)$	51.578	51.524	51.470	51.416	51.363	51.309
$(0.5, 0.5)$	51.554	51.509	51.464	51.420	51.375	51.331
$(0.4, 0.6)$	51.534	51.499	51.463	51.428	51.393	51.358
$(0.3, 0.7)$	51.520	51.494	51.467	51.441	51.415	51.389
$(0.2, 0.8)$	51.510	51.493	51.476	51.458	51.441	51.424

(0.1, 0.9)	51.505	51.497	51.488	51.480	51.471	51.462
(0, 1)	51.505	51.505	51.505	51.505	51.505	51.505

The peak day is day $31 - 36$, depending on the reach ratio (λ) and the resource allocation decision (a_H and a_L). When $a_L = 1$, the peak day is day 33.

$R_0 = 3.0$ ($\beta^S = 0.253677, \beta^A = 19025775$)

(a_H, a_L)	Reach ratio (λ)						
	0.395	0.4	0.405	0.41	0.415	0.42	0.425
(1, 0)	60.213	60.125	60.037	59.949	59.861	59.773	59.685
(0.9, 0.1)	60.165	60.087	60.008	59.929	59.851	59.772	59.694
(0.8, 0.2)	60.123	60.053	59.984	59.915	59.845	59.776	59.707
(0.7, 0.3)	60.086	60.026	59.965	59.905	59.845	59.785	59.725
(0.6, 0.4)	60.054	60.003	59.952	59.900	59.849	59.798	59.747
(0.5, 0.5)	60.027	59.985	59.942	59.900	59.858	59.816	59.773
(0.4, 0.6)	60.005	59.971	59.938	59.904	59.871	59.837	59.804
(0.3, 0.7)	59.988	59.963	59.938	59.913	59.888	59.863	59.838
(0.2, 0.8)	59.975	59.958	59.942	59.925	59.908	59.892	59.875
(0.1, 0.9)	59.966	59.958	59.950	59.941	59.933	59.925	59.917
(0, 1)	59.961	59.961	59.961	59.961	59.961	59.961	59.961

The peak day is day $30 - 33$, depending on the reach ratio (λ) and the resource allocation decision (a_H and a_L). When $a_L = 1$, the peak day is day 31.

b. The impact of the time that vaccine-L becomes available ( )

In Figure S2, each contour plot shows the infection attack rate (IAR) under different reach ratios,   (x-axis), and resource allocation to vaccine-H,   (y-axis) with a specified time that vaccine-L becomes available ( ). In each contour plot, there is a reach ratio, at which the shape of the contour line changes from convex-increasing to convex-decreasing, which is denoted as   . To minimize the IAR,   (i.e.,   ) if   and   otherwise. As   increases, the   moves leftward, indicating the case that more resource-intensive vaccine-H receives the entire allocation as the time that vaccine-L becomes available gets delayed.

(a)   (b)   (c)   (d)

(e)   (f)   (g)   (h)

Figure S2: Contour plots of infection attack rate (x-axis: reach ratio,   ; y-axis: resource allocation to vaccine-H,   ) under different times that vaccine-L becomes available   .

Table S3 shows $\hat{\lambda}_{IAR}$, $\hat{\lambda}_{PP}$, $\tilde{\lambda}_{IAR}$, and $\tilde{\lambda}_{PP}$ under different times that vaccine-L becomes available. When the reach ratio is between $\hat{\lambda}_{IAR}$ and $\tilde{\lambda}_{IAR}$, there exists an optimal combination of resource allocation to both vaccine types (i.e., $0 < a_H, a_L < 1$) that minimizes the IAR. Similarly, when the reach ratio is between $\hat{\lambda}_{PP}$ and $\tilde{\lambda}_{PP}$, there exists an optimal combination of resource allocation to both vaccine types (i.e., $0 < a_H, a_L < 1$) that minimizes the peak percentage. Note that when $t_L \geq 43$, the peak percentage when $a_L = 1$ does not change. This is because vaccine-L becomes available after the peak day, and, therefore, the peak percentage is the same as in the absence of any vaccine. When $t_L = 36$, $\hat{\lambda}_{PP}$ does not exist, which indicates that vaccine-H receives partial or entire allocation even if it is extremely resource-intensive. When $t_L \geq 43$, $\tilde{\lambda}_{PP}$ does not exist; this indicates that vaccine-H receives the entire resource allocation no matter how resource-intensive it is.

Table S3: Identification of reach ratio thresholds under different times that vaccine-L becomes available

Vaccine-L Time of Availability (t_L)	IAR $a_L = 1$	Peak % (Day) $a_L = 1$	$\hat{\lambda}_{IAR}$	IAR $a_H = 1$[1]	$\tilde{\lambda}_{IAR}$	IAR $a_H = 1$[2]	$\hat{\lambda}_{PP}$	Peak % (Day) $a_H = 1$[3]	$\tilde{\lambda}_{PP}$	Peak % (Day) $a_H = 1$[4]
1[5]	35.070	0.49653 (31)	0.780	35.130	0.785	35.058	0.790	0.49661 (31)	0.795	0.49592 (31)
8	37.081	0.53495 (32)	0.645	37.195	0.655	37.035	0.530	0.53495 (33)	0.540	0.53416 (33)
15	38.968	0.57021 (33)	0.530	39.116	0.550	38.771	0.320	0.57396 (36)	0.350	0.56809 (35)
22	40.716	0.60086 (34)	0.425	41.009	0.455	40.454	0.165	0.60628 (38)	0.210	0.59657 (37)
29	42.311	0.62535 (36)	0.335	42.743	0.375	41.959	0.070	0.62811 (39)	0.095	0.62225 (38)
36	43.740	0.64289 (37)	0.270	44.062	0.310	43.244	-	-	0.020	0.64029 (39)
43	44.994	0.64521 (39)	0.200	45.548	0.250	44.480	-	-	-	-
50	46.070	0.64521 (39)	0.155	46.539	0.200	45.548	-	-	-	-
57	46.970	0.64521 (39)	0.115	47.445	0.160	46.428	-	-	-	-

[1] IAR under $\lambda = \hat{\lambda}_{IAR}$ and $a_H = 1$
[2] IAR under $\lambda = \tilde{\lambda}_{IAR}$ and $a_H = 1$
[3] Peak percentage under $\lambda = \hat{\lambda}_{PP}$ and $a_H = 1$
[4] Peak percentage under $\lambda = \tilde{\lambda}_{PP}$ and $a_H = 1$
[5] This scenario assumes that vaccine-L and vaccine-H become available on the same day. Unlike any other scenarios, the optimal allocation decision in this scenario can be inferred without an epidemiological model. A decision-maker can minimize the IAR by choosing a resource allocation such that the number of individuals who are *vaccinated and fully protected against the disease* on each day is maximized (i.e., (a_H, a_L) s.t. $e_H a_H \lambda K + e_L a_L K$ is maximized).

c. The impact of the efficacy levels of vaccine-H (   )

Figure S3 shows the change in infection attack rate (IAR) with respect to the efficacy level of vaccine-H when the reach ratio is fixed at 0.43. IAR when   is labeled on the figure. For a linear increase in the efficacy level of vaccine-H, the reduction in IAR slowly decreases for all   . The result stays robust under different reach ratios.

Figure S3: Infection attack rate (%) with respect to the efficacy for vaccine-H when

Figure S4 shows the IAR under different efficacy levels of vaccine-H (　) and reach ratio　). Under a fixed　, IAR decreases as　increases. The rate of reduction in IAR, however, decreases as　increases. Under a fixed　, a higher　leads to a greater reduction in IAR.

Figure S4: Infection attack rate (%) with respect to the efficacy for vaccine-H

Table S4 shows $\hat{\lambda}_{IAR}$, $\hat{\lambda}_{PP}$, $\tilde{\lambda}_{IAR}$, and $\tilde{\lambda}_{PP}$ under different efficacies for vaccine-H. Both vaccines are allocated resources if the reach ratio is between $\hat{\lambda}_{IAR}$ and $\tilde{\lambda}_{IAR}$ (or between $\hat{\lambda}_{PP}$ and $\tilde{\lambda}_{PP}$). When $a_L = 1$, the level of infection attack rate is 40.716% and the peak percentage is 0.60086% on day 34, regardless of the level of efficacy of vaccine-H. As the efficacy level increases, all the reach ratio thresholds decrease, and the IAR and peak percentage when $a_H = 1$ decrease.

Table S4: Identification of reach ratio thresholds under different efficacies for vaccine-H

Vaccine-H Efficacy (%)	Vaccine-L				Vaccine-H			
	$\hat{\lambda}_{IAR}$	IAR when $a_H = 1$	$\hat{\lambda}_{PP}$	Peak % (Day) when $a_H = 1$	$\tilde{\lambda}_{IAR}$	IAR when $a_H = 1$	$\tilde{\lambda}_{PP}$	Peak % (Day) when $a_H = 1$
85	0.450	40.998	0.175	0.60612 (38)	0.480	40.472	0.220	0.59692 (37)
86	0.445	40.996	0.175	0.60570 (38)	0.475	40.465	0.220	0.59642 (37)
87	0.440	40.996	0.170	0.60637 (38)**	0.47	40.459	0.215	0.59696 (37) **
88	0.435	40.998*	0.170	0.60596 (38)	0.465	40.455	0.215	0.59647 (37)
89	0.43	41.003*	0.165	0.60667 (38) **	0.46	40.454	0.210	0.59704 (37) **
90	0.425	41.009*	0.165	0.60628 (38)	0.455	40.454	0.210	0.59657 (37)
91	0.42	41.017*	0.165	0.60588 (38)	0.45	40.456*	0.210	0.59609 (37)
92	0.415	41.028*	0.160	0.60664 (38) **	0.445	40.461*	0.205	0.59671 (37) **
93	0.41	41.040*	0.160	0.60626 (38)	0.44	40.467*	0.205	0.59624 (37)
94	0.41	40.957	0.160	0.60587 (38)	0.435	40.475*	0.200	0.59689 (37) **
95	0.405	40.972*	0.155	0.60668 (38) **	0.43	40.485*	0.200	0.59644 (37)

*: The reported IAR level in the table is higher than the IAR under a lower vaccine-H efficacy (e_H). This is because, as e_H increases, the threshold of the reach ratio ($\hat{\lambda}_{IAR}$ and $\tilde{\lambda}_{IAR}$), decreases. Under the same reach ratio λ, the IAR decreases as e_H increases (e.g., under $\lambda = 0.44$ and $e_H = 88\%$, the IAR when $a_H = 1$ is 40.907%, which is lower than the IAR of 40.996% under $\lambda = 0.44$ and $e_H = 87\%$).

**: The reported peak percentage in the table is higher than the peak percentage under a lower vaccine-H efficacy (e_H). This is because, as e_H increases, the threshold of the reach ratio ($\hat{\lambda}_{PP}$ and $\tilde{\lambda}_{PP}$), decreases. Under the same reach ratio λ, the peak percentage decreases as e_H increases.

D. Alternative Scenarios

We considered alternative scenarios, changing the settings of the main scenario: when (i) vaccine-H became available later than vaccine-L and (ii) vaccine-H became available sooner than vaccine-L as in the main scenario but both vaccines were delayed.

a. Vaccine-H becomes available later than vaccine-L

In this alternative scenario, keeping all other parameters the same as in the main scenario, we made vaccine-L became available on day 1 and varied the time that vaccine-H became available (later than vaccine-L). We also varied the reach ratio within the range of 0.005 and 3.00 with a discrete step size of 0.005 in this alternative scenario.

Table S5: Reach ratio thresholds under different times that vaccine-H becomes available

Vaccine-H Available Time	$\hat{\lambda}_{IAR}$	IAR $a_H = 1$	$\hat{\lambda}_{PP}$	Peak % (Day) $a_H = 1$	$\tilde{\lambda}_{IAR}$	IAR $a_H = 1$	$\tilde{\lambda}_{PP}$	Peak % (Day) $a_H = 1$
8	0.945	35.178	1.200	0.49923 (28)	0.960	35.010	1.275	0.49381 (28)
15	1.175	35.298	2.185	0.50814 (26)	1.235	34.809	> 3.0	----
22	1.490	35.612	> 3.0	----	1.720	34.341	> 3.0	----
29	1.945	36.083	> 3.0	----	2.765	33.362	> 3.0	----

The peak percentage when the corresponding threshold exceeds 3.00 is omitted

When $a_L = 1$ (i.e., $a_H = 0$), IAR is 35.070% and the peak percentage is 0.49653% on day 31. These results are not affected by the time that vaccine-H becomes available because vaccine-H receives no allocation.

b. Both vaccines become available later than in the main scenario
  i. Scenario-A

- Initial Condition:

  o Both vaccine-H and vaccine-L become available 14 days later than in the main scenario
    (i.e., day 15 and day 36, respectively).

  o On day 15, the population size of each compartment is as follows:

S	89.199%
I^S	1.873%
I^A	0.924%
Q	0.544%
R	7.323%
D	0.137%
V_H, V_L, S_H, S_L	0%

  o Cumulative number of cases is 10.42% and the active number of cases is 2.797% of the
    total population.

Table S6: Infection attack rate (IAR) in percentage under different reach ratios and resource allocation decisions when vaccine-H and vaccine-L become available 14 days later than in the main scenario

(a_H, a_L)	Reach ratio (λ)						
	0.375	0.38	0.385	0.39	0.395	0.40	0.405
$(1, 0)$	44.164	44.094	44.025	43.957	43.888	43.820	43.752
$(0.9, 0.1)$	44.117	44.056	43.995	43.934	43.873	43.812	43.752
$(0.8, 0.2)$	44.077	44.023	43.969	43.916	43.863	43.810	43.757
$(0.7, 0.3)$	44.042	43.996	43.949	43.903	43.857	43.811	43.766
$(0.6, 0.4)$	44.013	43.973	43.934	43.895	43.856	43.817	43.779
$(0.5, 0.5)$	43.988	43.956	43.924	43.892	43.860	43.827	43.796
$(0.4, 0.6)$	43.968	43.943	43.917	43.892	43.867	43.841	43.816
$(0.3, 0.7)$	43.953	43.934	43.915	43.896	43.877	43.859	43.840
$(0.2, 0.8)$	43.941	43.929	43.917	43.904	43.892	43.879	43.867
$(0.1, 0.9)$	43.934	43.928	43.922	43.916	43.909	43.903	43.897
$(0, 1)$	43.930	43.930	43.930	43.930	43.930	43.930	43.930

The peak day is day $17 - 23$, depending on the reach ratio (λ) and the resource allocation decision (a_H and a_L). When $a_L = 1$, the peak day is day 23.

ii. Scenario-B

- Initial Condition:

  o Both vaccine-H and vaccine-L become available 23 days later than in the main scenario (i.e., day 24 and day 45, respectively).

  o On day 24, the population size of each compartment is as follows:

S	84.439%
I^S	2.403%
I^A	1.183%
Q	0.720%
R	11.081%
D	0.174%
V_H, V_L, S_H, S_L	0%

  o Cumulative number of cases is 15.07% and the active number of cases is 3.586% of the total population.

Table S7: Infection attack rate (IAR) in percentage under different reach ratios and resource allocation decisions when vaccine-H and vaccine-L become available 23 days later than in the main scenario

(a_H, a_L)	Reach Ratio (λ)							
	0.345	0.35	0.355	0.36	0.365	0.37	0.375	0.38
(1, 0)	45.676	45.620	45.564	45.508	45.452	45.397	45.341	45.286
(0.9, 0.1)	45.636	45.587	45.537	45.487	45.438	45.389	45.340	45.291
(0.8, 0.2)	45.602	45.558	45.515	45.472	45.428	45.385	45.342	45.299
(0.7, 0.3)	45.573	45.535	45.497	45.460	45.423	45.385	45.348	45.311
(0.6, 0.4)	45.548	45.516	45.484	45.452	45.421	45.389	45.358	45.326
(0.5, 0.5)	45.527	45.501	45.475	45.449	45.423	45.397	45.371	45.345
(0.4, 0.6)	45.510	45.489	45.469	45.448	45.428	45.407	45.386	45.366
(0.3, 0.7)	45.497	45.482	45.466	45.451	45.436	45.420	45.405	45.390
(0.2, 0.8)	45.487	45.477	45.467	45.457	45.447	45.437	45.427	45.417
(0.1, 0.9)	45.481	45.476	45.471	45.466	45.461	45.456	45.451	45.446
(0, 1)	45.477	45.477	45.477	45.477	45.477	45.477	45.477	45.477

The peak day is day $10 - 15$, depending on the reach ratio (λ) and the resource allocation decision (a_H and a_L). When $a_L = 1$, the peak day is day 15, which is before vaccine-L becomes available.